Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus.

We developed a mathematical simulation model to anticipate outcomes from an upcoming trial of targeted, preemptive cytomegalovirus (CMV) therapy in high-risk, human immunodeficiency virus (HIV)-infected patients identified by means of CMV polymerase chain reaction screening. We estimated the costs and consequences of CMV prophylaxis in patients with CD4(+) counts < or =100 cells/microL under various assumptions regarding disease progression, complication rates, drug effects, and costs. Without CMV preemptive therapy, lifetime costs average $44,600 with expected duration of survival of 19.16 quality-adjusted life-months and 213 CMV cases per 1000 patients. Targeted preemptive therapy with orally administered valganciclovir increases costs and duration of survival to $46,900 and 19.63 quality-adjusted life-months, respectively. CMV cases decrease to 174 per 1000 patients. The cost per quality-adjusted life-year gained is $59,000. This result compares favorably with other strategies in end-stage HIV disease but hinges on valganciclovir cost and efficacy assumptions and the absence of minimally effective salvage antiretroviral therapy for HIV. The upcoming trial should resolve the clinical uncertainty surrounding some of these assumptions.

[1]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[2]  M C Weinstein,et al.  The cost effectiveness of combination antiretroviral therapy for HIV disease. , 2001, The New England journal of medicine.

[3]  P. Harrigan,et al.  Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens , 2001, AIDS.

[4]  C. Berg,et al.  Abortion surveillance--United States, 1999. , 2002, Morbidity and mortality weekly report. Surveillance summaries.

[5]  M. Weinstein,et al.  THE COST-EFFECTIVENESS OF PROPHYLAXIS FOR MYCOBACTERIUM AVIUM COMPLEX IN AIDS , 1999, International Journal of Technology Assessment in Health Care.

[6]  P. Volberding,et al.  Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. , 1999, The Journal of infectious diseases.

[7]  M. Weinstein,et al.  The Costs, Clinical Benefits, and Cost-Effectiveness of Screening for Cervical Cancer in HIV-Infected Women , 1999, Annals of Internal Medicine.

[8]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[9]  Kenneth A. Freedberg,et al.  A Monte Carlo Simulation of Advanced HIV Disease , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[10]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[11]  T. Louis,et al.  A randomized, placebo‐controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV‐infected individuals , 1998 .

[12]  E. Sandström,et al.  Induction of specific T‐cell responses in HIV infection , 1998, AIDS.

[13]  S. Spector,et al.  Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. , 1998, The Journal of clinical investigation.

[14]  M C Weinstein,et al.  The cost-effectiveness of preventing AIDS-related opportunistic infections. , 1998, JAMA.

[15]  K. Freedberg,et al.  The Cost-Effectiveness of Fluconazole Prophylaxis against Primary Systemic Fungal Infections in AIDS Patients , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[16]  M A Fischl,et al.  A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. , 1997, The New England journal of medicine.

[17]  R. Chaisson,et al.  Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[18]  M. Jacobson,et al.  Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. , 1997, The New England journal of medicine.

[19]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[20]  H. Sacks,et al.  Cost‐effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing , 1997, AIDS.

[21]  C. Sabin,et al.  Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV‐positive patients at high risk of CMV disease , 1997, AIDS.

[22]  B. Hofmann,et al.  Development of cytomegalovirus (CMV) disease may be predicted in HIV‐infected patients by CMV polymerase chain reaction and the antigenemia test , 1997, AIDS.

[23]  S. Spector,et al.  Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. , 1997, The Journal of infectious diseases.

[24]  D. Havlir,et al.  Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. , 1996, The New England journal of medicine.

[25]  J. Chmiel,et al.  Survival from early, intermediate, and late stages of HIV infection. , 1996, JAMA.

[26]  D R Holtgrave,et al.  Threshold Analysis and Programs for Prevention of HIV Infection , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.

[27]  J. Fleishman,et al.  AIDS treatment costs during the last months of life: evidence from the ACSUS. , 1994, Health services research.

[28]  S. Homan,et al.  Determining Transition Probabilities , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[29]  H. Waskin,et al.  A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. , 1992, The New England journal of medicine.

[30]  T. Merigan.  Treatment of cytomegalovirus infection in the AIDS patient. , 1991, Transplantation proceedings.

[31]  H. Ms.  Cytomegalovirus and its role in the pathogenesis of acquired immunodeficiency syndrome. , 1991 .

[32]  H. Hosseinzadeh,et al.  Short-term treatment of rats with cyclosporin A causes the appearance of lymph node T cells that resemble cortical thymocytes. , 1991, Transplantation proceedings.

[33]  R. Schooley.  Cytomegalovirus in the setting of infection with human immunodeficiency virus. , 1990, Reviews of infectious diseases.

[34]  T. Merigan,et al.  Cytomegalovirus: where have we been and where are we going? , 1990, Reviews of infectious diseases.

[35]  H. Balfour,et al.  Management of cytomegalovirus disease with antiviral drugs. , 1990, Reviews of infectious diseases.

[36]  J. Phair,et al.  The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. , 1990, The New England journal of medicine.

[37]  J. Phair,et al.  The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. , 1987, American journal of epidemiology.

[38]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[39]  1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). , 1999, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[40]  E. Bowen.  Cytomegalovirus reactivation in patients infected with HIV: the use of polymerase chain reaction in prediction and management. , 1999, Drugs.

[41]  M. Youle,et al.  A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. , 1998, The Journal of infectious diseases.

[42]  C. Sabin,et al.  The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. , 1998, The Journal of infectious diseases.

[43]  M. Jacobson,et al.  Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. , 1998, AIDS.

[44]  A. Paltiel,et al.  Resource Allocation and the Funding of HIV Prevention , 1998 .

[45]  D. Cooper,et al.  A Randomized, Double-Blind Trial of Valaciclovir Prophylaxis for Cytomegalovirus Disease in Patients with Advanced Human Immunodeficiency Virus Infection , 1998 .

[46]  W. McIsaac,et al.  Effect of an Explicit Decision-Support Tool on Decisions to Prescribe Antibiotics for Sore Throat , 1998, Medical decision making : an international journal of the Society for Medical Decision Making.

[47]  David R. Holtgrave,et al.  Handbook of Economic Evaluation of HIV Prevention Programs , 1998, AIDS Prevention and Mental Health.

[48]  M C Weinstein,et al.  Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. , 1996, Medical care.

[49]  B. Spilker,et al.  Quality of life and pharmacoeconomics in clinical trials , 1996 .

[50]  F J Hellinger,et al.  Forecasts of the costs of medical care for persons with HIV: 1992-1995. , 1992, Inquiry : a journal of medical care organization, provision and financing.

[51]  Hellinger Fj,et al.  Forecasts of the costs of medical care for persons with HIV: 1992-1995. , 1992 .

[52]  S. Finkler.  The distinction between cost and charges. , 1982, Annals of internal medicine.

[53]  D. Commerce.  Statistical abstract of the United States , 1978 .